Table of Contents :
• Stock Rating & Target Price
• Investment Thesis
• Fundamental Models Used
• Company Description
• Corporate Timeline
• Key Metrics (KPI ) and Recently Reported Earnings Review
• Business Highlights, Strategic Announcements & Outlook
• Quarter-over-Quarter (Q-o-Q) and Year-over-Year (Y-o-Y) Growth Analysis
• Key Catalysts Driving Growth
• Historical Financial Statement Analysis & CAGR Trends
• Quarterly Key Financial Ratios and Performance Metrics
• Annual Financial Performance Analysis: Horizontal and Vertical Financial Analysis, Trends
• Financial Forecasts
• Annual Forecasts: Income Statement
• Annual Forecasts: Cash Flow Statements
• Net Debt Levels
• A Closer Look at DCF: Our Assumptions and Methodology
• Terminal Value Calculation
• Target Price Analysis
• Valuation Multiples
• Supplementary Valuation Analysis: Multiples Approach
• Scenario/Sensitivity Analysis – Base Case , Bull Case ,Bear Case
• Holistic Peer Review & Trading Comps: Financial Data, Operational Metrics, and Valuation Multiples
• Implied Price Per Share
• Ownership Activity/ Insider Trades
• Ownership Summary
• An analysis of ESG Risk Rating
• Key Professionals
• Key Board Members
• Key Risks Considerations
• Analyst Ratings
• Analyst Industry Views
• Disclosures
Neurocrine Biosciences (NBIX): INGREZZA Demand Inflects, CRENESSITY Launch Outperforms, and Late-Stage Pipeline Advances—What’s the Impact, Valuation Outlook & its 5 Key Catalysts?
Neurocrine’s Q1F25 results reflect a solid inflection in commercial momentum and early validation of a second revenue pillar. INGREZZA posted $545M in sales, in line with expectations, but notably delivered record new-to-brand patient starts despite Q1 friction (formulary churn, shipping week loss), signaling a resurgence in script momentum and supporting FY25 guidance of $2.5B–$2.6B. Expanded Medicare PD/HD coverage and full field force deployment offer incremental tailwinds into 2H. CRENESSITY materially outperformed in its first full quarter with $14.5M in sales and a 70% reimbursement success rate, driven by higher-than-anticipated uptake in pediatric CAH. We view early-cycle payer alignment and efficient access pathways as signals of launch quality, with prescriber breadth across community and academic endocrinologists adding depth. Capital allocation remains balanced, with $1.8B in cash supporting both share buybacks and R&D investment across late-stage programs, including Phase III starts for osavampator (MDD) and NBI-‘568 (schizophrenia). Additional catalysts—valbenazine readouts in schizophrenia and dyskinetic cerebral palsy—could de-risk future VMAT2 asset iterations. With pipeline breadth, commercial reacceleration, and operational scale, we see FY26 as a transition year toward multi-blockbuster diversification. Can Neurocrine convert CRENESSITY’s early momentum and INGREZZA’s resurgence into a durable dual-growth narrative that rerates valuation meaningfully higher?
